Serial measurement of serum cytokines, cytokine receptors and neopterin in leprosy patients with reversal reactions

Leprosy Review

Volumn 75, Issue 3, 2004, Pages 274-281

  Faber, W R ^a   Iyer, A M ^a   Fajardo, T T ^b   Dekker, T ^a   Villahermosa, L G ^b   Abalos, R M ^b   Das, P K ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Leonard Wood Memorial Center for Leprosy Research Philippines   (Philippines)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYTOKINE; CYTOKINE RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 4; INTERLEUKIN 5; MONOKINE; NEOPTERIN; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LEPROSY; PATIENT MONITORING; RADIOIMMUNOASSAY; REVERSAL REACTION;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; LEPROSTATIC AGENTS; LEPROSY, LEPROMATOUS; MALE; MIDDLE AGED; NEOPTERIN; PHILIPPINES; RECEPTORS, CYTOKINE;

EID: 5444274011     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Salgame P, Abrams JS, Clayberger C et al. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science, 1991; 254: 279-282.
2. Yamamura M, Uyemura K, Deans RJ et al. Defining protective responses to pathogens: Cytokine profiles in leprosy lesions. Science, 1991; 254: 277-279.
3. Moubasher AEA, Kamel NA, Zaden H, Abdel Raheem DE. Cytokines in leprosy, I. Serum cytokine profile in leprosy. Int J Dermatol, 1998; 37: 733-740.
4. Moubasher AEA, Kamel NA, Zaden H, Abdel Raheem DE. Cytokines in leprosy, II. Effect of treatment on serum cytokines in leprosy. Int J Dermatol, 1998; 37: 741-746.
5. Moraes MO, Sarno EN, Almeida AS et al. Cytokine mRNA expression in leprosy: a possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL). Scand J Immunol, 1999; 50: 541-549.
6. Manandhar R, Shrestha N, Butlin CR, Roche PW. High levels of inflammatory cytokines are associated with poor clinical response to steroid treatment and recurrent episodes of type 1 reactions in leprosy. Clin Exp Immunol, 2002; 128: 333-338.
7. Murr C, Widner B, Wirleitner B, Fuchs D. Neopterin as a marker for immune system activation. Curr Drug Metab, 2002; 3: 175-187.
8. Naafs B. Current views on reactions in leprosy. Ind J Lepr, 2000; 72: 97-122.
9. Verhagen CE, Wierenga EA, Buffing AAM et al. Reversal reaction in borderline leprosy is associated with a polarized shift to type 1-like Mycobacterium leprae T cell reactivity in lesional skin: a follow-up study. J Immunol, 1997; 159: 4474-4483.
10. Nath I, Vemuri N, Reddi AL et al. The effect of antigen presenting cells on the cytokine profiles of stable and reactional lepromatous leprosy patients. Immunol Lett, 2000; 75: 69-76.
11. Hamerlinck FFV, Klatser PR, Walsh DS et al. Serum neopterin as a marker for reactional states in leprosy. FEMS Immunol Med Microbiol, 1999; 24: 405-409.
12. Woloszczuk W, Troppmair J, Leiter E et al. Relationship of interferon-gamma and neopterin levels during stimulation with alloantigens in vivo and in vitro. Transplantation, 1986; 41: 716-719.
13. Huber C, Batchelor JR, Fuchs D et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med, 1984; 160: 310-316.
14. Fuchs D, Hausen A, Kofler M et al. Neopterin as an index of immune response in patients with tuberculosis. Lung, 1984; 162: 337-346.
15. Reibnegger G, Boonpucknavig V, Fuchs D et al. Urinary neopterin is elevated in patients with malaria. Trans R Soc Trop Med Hyg, 1984; 78: 545-546.
16. Naafs B. Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve damage. Int J Lepr Other Mycobact Dis, 1996; 64: S21-8.
17. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis, 1966; 34: 255-273.
18. Werner ER, Bichler A, Daxanbichler G et al. Determination of neopterin in serum and urine. Clin Chem, 1987; 33: 62-66.
19. Misra N, Murtaza A, Walker B et al. Cytokine profile of circulating T cells of leprosy patients reflects both indiscriminate and polarized T helper subsets: T-helper phenotype is stable and uninfluenced by related antigens of Mycobacterium leprae. Immunology, 1995; 86: 97-103.
20. Saha K, Chattopadhya D, Kashyup A et al. Enhanced response of serum IgG class of anti-PGL-I antibodies in leprosy patients during onset and following clinical remission of type 1 and type 2 reactions. Int J Lepr Other Mycobact Dis, 1995; 63: 105-109.
21. Little D, Khanolkar-Young S, Coulthart A et al. Immunohistochemical analysis of cellular infiltrate and gamma interferon, interleukin-12 and inducible nitric oxide synthase expression in leprosy type 1 reactions before and during prednisolone treatment. Infection and Immunity, 2001; 69: 3413-03417.
22. Beuria MK, Mohanty KK, Katoch K, Sengupta U. Determination of circulating IgG subclasses against lipoarabinomannan in the leprosy spectrum and reactions. Int J Lepr Other Mycobact Dis, 1999; 67: 422-428.
23. Sarno EN, Grau GE, Vieira LM, Nery JA. Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states. Clin Exp Immunol, 1991; 84: 103-108.
24. Sehgal VN, Bhattacharya SN, Chattopadhaya D, Sana K. Tumor necrosis factor: status in reactions in leprosy before and after treatment. Int J Dermatol, 1993; 32: 436-439.
25. Munk ME, Anding P, Schettini APM et al. Soluble tumor necrosis factor-alpha receptors in sera from leprosy patients. Infect Immun, 1999; 67: 423-425.
26. Tung KS, Umland E, Matzner P et al. Soluble serum interleukin 2 receptor levels in leprosy patients. Clin Exp Immunol, 1987; 69: 10-15.
27. Sehgal VN, Bhattacharya SN, Shah Y et al. Soluble interleukin receptors: levels in leprosy, and during and after type 1 (lepra) and type 2 (ENL) reactions. Lepr Rev, 1991; 62: 262-268.
28. Fuchs D, Weiss G, Reibnegger G, Wachter H. The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious and malignant diseases. Crit REv Clin Lab Sci, 1992; 29: 307-341.
29. Schafer AJ, Daniel G, Driekorn K, Opelz G. Assessment of plasma neopterin in clonical kidney transplantation. Transplantation, 1983; 36: 650-653.
30. Niederwieser D, Fuchs D, Hausen A et al. Neopterin as a new biochemical marker in clinical assessment of ulcerative colitis. Immunobiology, 1985; 170: 320-326.
31. Hannonen P, Tikanoja S, Hakola M et al. Urinary neopterin reflects clinical activity in patient with rheumatoid arthritis. Scand J Rheumatol, 1986; 15: 148-152.
32. Prior C, Fuchs D, Hausen A et al. Urinary neopterin, a marker of clinical activity in patients with Crohn's disease. Clin Chim Acta, 1986; 155: 11-22.
33. Lambin P, Desjobert H, Debbia M et al. Serum neopterin and beta 2-microglobulin in anti-HIV positive blood donors. Lancet, 1986; 2: 1216.
34. Reibnegger G, Fuchs D, Hausen A et al. The dependence of cell mediated immune activation in malaria on age and endemicity. Trans R Soc Trop Med Hyg, 1987; 81: 729-733.
35. WHO Expert Committee on Leprosy. World Health Organ Tech Rep Ser, 1988; 768: 1-51.